Financial Performance - The company reported a revenue of RMB 10.5 billion for the first half of 2023, representing a year-on-year increase of 15%[2]. - The company reported a revenue of 5.2 billion RMB for the first half of 2023, representing a year-on-year growth of 15%[8]. - Mindray's revenue for the first half of 2023 reached approximately RMB 8.5 billion, representing a year-on-year increase of 15%[12]. - The company reported operating revenue of CNY 18,475,773,496, an increase of 20.32% compared to the same period last year[25]. - The company's net profit attributable to shareholders was around RMB 1.5 billion, reflecting a growth of 12% compared to the same period last year[12]. - The company aims to achieve a revenue target of RMB 18 billion for the full year 2023, representing a growth rate of 10%[12]. - The company expects a revenue growth of 10-15% for the full year 2023, driven by new product launches and market expansion strategies[10]. - The company reported a total revenue of RMB 575,179 million for the first half of 2023, with a net profit of RMB 29,041 million, reflecting a significant increase compared to the previous period[181]. Gross Profit and Margins - The gross profit margin improved to 60%, up from 58% in the same period last year[3]. - The gross margin for the first half of 2023 was reported at 45%, a slight increase from 43% in the previous year[10]. - Mindray's gross margin improved to 60%, up from 58% in the previous year, due to enhanced operational efficiency and cost management[12]. - The gross profit margin for life information and support products was 67.16%, an increase of 1.41% year-on-year, while the gross profit margin for in vitro diagnostic products was 62.63%, up 1.31%[166]. Research and Development - Research and development expenses increased by 30% to RMB 1.2 billion, focusing on advanced medical technologies[3]. - The R&D investment for the first half of 2023 was 800 million RMB, accounting for 15% of total revenue, focusing on innovative medical technologies[9]. - The total R&D expenditure for the first half of 2023 was approximately RMB 1.2 billion, accounting for 14% of total revenue, indicating a strong commitment to innovation[12]. - The company achieved a 40.07% year-on-year increase in R&D investment, reaching CNY 204,003.44 million, which accounts for 11.04% of the revenue during the same period[35]. - In 2023, the company invested CNY 2,040.03 million in R&D, representing a year-on-year increase of 40.07%[150]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[3]. - Mindray's market expansion efforts led to a 20% increase in international sales, contributing to 40% of total revenue[12]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[3]. - The company is exploring strategic acquisitions to enhance its product portfolio and market presence, particularly in emerging markets[12]. - The company aims to enhance its market share by continuously investing in R&D and improving product cost-effectiveness, aligning with national policies to promote high-quality medical resources[72]. Product Development and Launches - New product launches include a state-of-the-art ultrasound system, expected to contribute an additional RMB 1 billion in revenue by the end of 2024[3]. - A new line of advanced monitoring devices is set to launch in Q4 2023, anticipated to increase market competitiveness[8]. - The company launched several new products, including advanced ultrasound systems and automated laboratory solutions, which are expected to drive future growth[12]. - The company has developed industry-leading cardiac markers, including high-sensitivity troponin I (hs-TnI) and NT-pro BNP, enhancing sensitivity and precision for cardiovascular disease management[46]. - The company has introduced several new products, such as the fully automated biochemical analyzer and various hepatitis virus assay kits, all classified under Class III, with registration dates in April 2023[141]. User Growth and Customer Base - User data showed an increase in the number of active users to 1.2 million, a growth of 20% compared to the previous year[3]. - The number of users for the company's medical devices increased by 20% compared to the same period last year, reaching 1.5 million active users[9]. - Mindray's customer base grew by 25% in the first half of 2023, with significant increases in both hospital and outpatient segments[12]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year[2]. - The company has a remaining balance of RMB 1,518,171,439.04 in the special account for raised funds[178]. - The total investment during the reporting period was ¥2,265,242,844, a significant increase of 119.97% compared to ¥1,029,817,327 in the same period last year[172]. - The company has allocated RMB 29,485.69 million of surplus raised funds for daily operational activities after completing several investment projects[181]. Risk Management - Risk factors identified include regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[3]. - The company is exposed to foreign exchange risks, particularly from fluctuations in RMB against USD and EUR, which can affect revenue and profit margins[191]. - The company emphasizes compliance and risk management in response to industry policy changes to mitigate operational risks[190]. Compliance and Quality Management - The company has a comprehensive compliance management system certified by ISO 37001:2016, covering all aspects of its operations[150]. - The company has passed 59 quality system audits during the reporting period, maintaining high standards in product quality management[156]. - The company has established a global intellectual property protection system since 2016, enhancing its market competitiveness[152]. Strategic Partnerships and Collaborations - The company is collaborating with top hospitals to research AI applications in patient monitoring and respiratory devices[43][44]. - The company has established long-term partnerships with leading medical institutions in countries such as the USA, UK, Italy, and Germany[159]. - The company has established partnerships with various universities and research institutions, contributing to its technological innovation and product development[63]. Investor Relations and Communication - The company held multiple investor meetings and calls throughout January and February 2023, engaging with various institutional investors[200]. - The focus of discussions included the impact of IVD centralized procurement on the company's product offerings and market positioning[200]. - The company is dedicated to maintaining transparency and providing detailed updates to investors regarding its performance and future outlook[200].

深圳迈瑞生物医疗电子股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用 方名称 占用方与上 市公司的关 联关系 上市公司核算 的会计科目 2023 年期 初占用资金 余额 2023 半年度占 用累计发生金 额（不含利 息） 2023 半年度 占用资金的利 息（如有） 2023 半年度 偿还累计发 生金额 2023 半年度 期末占用资 金余额 占用形成 原因 占用性质 控股股东、实际控制人及 其附属企业 无 不适用 不适用 - - - - - 不适用 不适用 前控股股东、实际控制人 及其附属企业 无 不适用 不适用 - - - - - 不适用 不适用 其他关联方及附属企业 无 不适用 不适用 - - - - - 不适用 不适用 总计 - - - - - 其它关联资金往来 资金往来 方名称 往来方与上 市公司的关 联关系 上市公司核算 的会计科目 2023 年期 初往来资金 余额 2023 半年度往 来累计发生金 额（不含利 息） 2023 半年度 往来资金的利 息（如有） 2023 半年度 偿还累计发 生金额 2023 半年度 期末往来资 金余额 ...

深圳迈瑞生物医疗电子股份有限公司独立董事 关于第八届董事会第三次会议相关事项的独立意见 二、关于公司控股股东及其他关联方资金占用、公司对外担保情况的独立意 见 经核查： 1、报告期内，公司不存在控股股东及其他关联方占用公司资金的情况，也 不存在以前年度发生并累计至 2023 年 6 月 30 日的控股股东及其他关联方占用公 司资金等情况，未发现其他将资金直接或间接地提供给关联方使用的各种情形。 2、报告期内，公司不存在为控股股东及其关联方提供担保的情况，也不存 在任何违规对外担保事项。公司严格控制对外担保风险，不存在因对外担保承担 连带清偿责任的可能，也不存在违反《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等规定 的情形。 独立董事：梁沪明、周先意、胡善荣、高圣平、许静、孔昱 2023 年 8 月 30 日 根据《上市公司独立董事规则》以及《深圳迈瑞生物医疗电子股份有限公司 章程》等规定，我们作为深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"） 的独立董事，对公司第八 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-049 经审议，监事会认为：2023年半年度，公司募集资金的存放和使用符合中国证监会、 深圳证券交易所、公司《募集资金管理办法》等关于上市公司募集资金存放和使用的相关 规定，不存在募集资金存放和使用违规的情形。 一、监事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届监事会第三次会议于 2023年8月28日在迈瑞总部大厦会议室以现场结合通讯方式召开，会议通知于2023年8月18 日以电子邮件等方式送达全体监事。 会议由公司监事会主席汤志先生主持。本次会议应出席监事3人，实际到会监事3人， 其中监事冀强先生以通讯表决方式参会。本次会议的召集、召开符合《中华人民共和国公 司法》和《深圳迈瑞生物医疗电子股份有限公司章程》等有关规定。 二、监事会会议审议情况 经与会监事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于<2023年半年度募集资金存放与实际使用情况的专项报告>的议案》 深圳迈瑞生物医疗电子股份有限公司 第八届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 ...

深圳迈瑞生物医疗电子股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届董事会第三次会议于 2023年8月28日上午11:00在香港文华东方酒店会议室以现场结合通讯方式召开，会议通知于 2023年8月18日以电子邮件等方式送达全体董事。 会议由公司董事长李西廷先生主持。本次会议应出席董事人数11人，实际出席董事人 数11人，其中董事吴昊先生以通讯表决方式参会，董事成明和先生因个人原因未能亲自出 席会议，授权委托董事李西廷先生代为出席并行使表决权。本次会议的召集、召开符合《中 华人民共和国公司法》和《深圳迈瑞生物医疗电子股份有限公司章程》等有关规定。 二、董事会会议审议情况 证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-048 公司全体独立董事对本议案发表了同意的独立意见。 具体内容详见公司同日刊载于巨潮资讯网（www.cninfo.com.cn）上的相关公告。 表决结果：同意票11票、反对票0票、弃权票0票。 2、审议通 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关规定，现将 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）2023年半年度募集资金存放与实 际使用情况报告如下： 证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-050 深圳迈瑞生物医疗电子股份有限公司 2023年半年度募集资金存放与实际使用情况的专项报告 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"证监会"）签发的《关于核准深圳迈瑞生物 医疗电子股份有限公司首次公开发行股票的批复》（证监许可[2018] 1436号文），公司于2018 年10月向社会公众发行人民币普通股121,600,000股，每股发行价格为人民币48.80元，募集 资金总额为人民币5,934,080,000.00元。扣除承销保荐费用人民币138,396,226.41元，实际收 到募集资金人民币5,795,683,773.59元。扣除发行中介费用人民币43,88 ...

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 证券代码：300760 证券简称：迈瑞医疗 编号：2023-005 投资者关系活动记录表 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 ☑路演活动 活动类别 ☑现场参观 ☑其他 电话会议、券商策略会 参与单位名 169 家机构 265 名参与人员，详见附件清单。 称及人员姓 名 时间 2023 年 7 月 3-7 日、7 月 10-14 日、7 月 17 日、7 月 19-21 日、7 月 24-28 日、7 月 31 日 深圳市南山区高新技术产业园区科技南十二路迈瑞大厦 洛杉矶、纽约、波士顿、上海投资人办公室 地点 券商策略会会场 董事会秘书李文楣 上市公司接 投资者关系团队钱宇浩、杨惠茹 待人员姓名 1、互动提问 问：公司近日公告拟收购境外标的 DiaSys Diagnostic 75%的股权，请 问这笔并购对公司的意义是什么？为什么选择收购 DiaSys Diagnostic？ 答：体外诊断是支撑公司未来长远发展的核心业务之一，而实现体外诊 投资者关系 断全面国际化更是其中不得不迈出的关键一步。但一直以来，海外供 ...

Group 1: Investor Relations Activities - The investor relations activities included specific object research, performance briefings, roadshows, and site visits, with a total of 515 institutions and 862 participants involved [2] - The activities took place from May 4 to June 30, 2023, across various locations including Shenzhen and multiple hotels in Shanghai [2][3] Group 2: Business Performance and Growth - The company reported a strong recovery in routine business activities in Q2 2023, leading to significant growth in IVD and medical imaging sectors [3] - The chemical luminescence business achieved nearly 30% growth last year, exceeding 3 billion RMB, with domestic market growth over 25% and international market growth over 50% [4] - The company expects continued high-speed growth in chemical luminescence installations and reagent consumption in 2023 [4] Group 3: ESG Ratings and Sustainability Efforts - The company improved its MSCI ESG rating from BB to AA, the highest rating for A-share listed companies, reflecting advancements in environmental, social, and governance practices [3] - A carbon reduction target was set to decrease carbon intensity by 25% from 2021 levels by 2030, alongside a comprehensive carbon reduction plan [4] Group 4: Market Expansion and Competitive Landscape - The company has seen a significant increase in market share due to participation in centralized procurement projects, achieving over 85% growth in chemical luminescence business in Anhui province [6] - The market share for the chemical luminescence business in Anhui has risen to over 20%, with plans for further expansion in other regions [6][7] - The company anticipates that the ongoing trend of centralized procurement will continue, providing opportunities for market share growth [7] Group 5: Future Outlook and Strategic Initiatives - The company identified 245 billion RMB in pending medical infrastructure opportunities, expecting these projects to contribute to growth over the next three years [8] - The government plans to allocate 38 billion RMB for local government special bonds in 2023, which is expected to support healthcare infrastructure development [8] - The company aims to enhance its product competitiveness and market penetration in high-end hospitals and overseas markets [6][7]

Group 1: Market Position and Growth - The medical device market in China is rapidly growing, becoming the second largest globally, driven by an aging population and improved healthcare systems [2][3] - The company covers nearly 110,000 medical institutions in China and over 99% of top-tier hospitals, indicating a high product penetration rate [2] - The company has achieved the largest market share in several product categories, including blood cell diagnostics and monitoring devices [3] Group 2: Financial Performance - In Q1 2023, the company reported a net cash flow from operating activities of CNY 13.3 billion, a year-on-year increase of 53.3% [4][5] - For the year 2022, the net cash flow from operating activities was CNY 121.41 billion, up 34.92% from the previous year [5][6] - The company plans to distribute a cash dividend of CNY 45 per 10 shares for the 2022 fiscal year, totaling approximately CNY 54.56 billion, which represents 56.79% of the net profit attributable to shareholders [4][6] Group 3: Research and Development - The company invests about 10% of its revenue in R&D, with cumulative investments nearing CNY 110 billion over five years [4] - In Q1 2023, R&D expenditure was CNY 9.38 billion, reflecting a year-on-year growth of 26.30% [4] - Future R&D focuses include life information and support, in vitro diagnostics, and minimally invasive surgery, with significant product launches expected in 2023 [4] Group 4: Competitive Advantages - The company's core competencies include systematic R&D innovation, advanced quality management, and a comprehensive after-sales service system [3] - The company has established a strong brand presence in international markets, benefiting from over 22 years of market cultivation [3] - The company aims to continue enhancing its competitive edge to reach the top 20 global medical device companies [3]